"Biocept provides a great opportunity to be part of an organization that is making excellent progress in developing a menu of blood-based tests with the potential to garner as much information about the genomic status of a tumor as an invasive surgical tissue biopsy," Dr. Poole said. "I believe the liquid biopsy will play an increasingly important role in cancer treatment as blood samples are easy to obtain from patients in the physician's office, negating the need for a risky and expensive surgical procedure in the hospital. I am excited to join the Biocept team and help enhance the Company's cutting edge diagnostics in order to improve patient outcomes while reducing testing and treatment costs."
Dr. Poole holds a doctorate in Cancer Genetics from the University of Illinois at Chicago. He was a post-doctoral fellow at the University of California, Irvine, where he developed diagnostic assays for inborn errors of metabolism and other human metabolic diseases.
Sentiment: Strong Buy
..He probably had to buy some gift to his old wife...Or for some young girl..
It was clear even before the numbers released today that Symbis will be the game changer of this company...I begin to believe that part of the presented backlog will appear after Symbis approval..
Even with the full conversion of the warrants...Bioc would have a market cap of around 70 millions ,but with 10 millions more in cash...
...Symbis can be competitor for Isrg,but Isrg won'te be competitor for Symbis...The robotic surgery system with MRI intraoperative is a complete different approach...It will begin with brain surgery and will continue with other applications,and without competitors at least for several years..
Sentiment: Strong Buy
...More validation for liquid biopsy in all the possible applications...Very big market very soon for liquid biopsy producers..
Sentiment: Strong Buy
2014 Dec 26. pii: S1574-7891(14)00288-9. doi: 10.1016/j.molonc.2014.12.003. [Epub ahead of print]
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.
Lebofsky R1, Decraene C2, Bernard V3, Kamal M4, Blin A3, Leroy Q3, Rio Frio T3, Pierron G5, Callens C5, Bieche I5, Saliou A1, Madic J1, Rouleau E5, Bidard FC6, Lantz O7, Stern MH8, Le Tourneau C9, Pierga JY10.
Cell-free tumor DNA (ctDNA) has the potential to enable non-invasive diagnostic tests for personalized medicine in providing similar molecular information as that derived from invasive tumor biopsies. The histology-independent phase II SHIVA trial matches patients with targeted therapeutics based on previous screening of multiple somatic mutations using metastatic biopsies. To evaluate the utility of ctDNA in this trial, as an ancillary study we performed de novo detection of somatic mutations using plasma DNA compared to metastasis biopsies in 34 patients covering 18 different tumor types, scanning 46 genes and more than 6800 COSMIC mutations with a multiplexed next-generation sequencing panel. In 27 patients, 28 of 29 mutations identified in metastasis biopsies (97%) were detected in matched ctDNA. Among these 27 patients, one additional mutation was found in ctDNA only. In the seven other patients, mutation detection from metastasis biopsy failed due to inadequate biopsy material, but was successful in all plasma DNA samples providing three more potential actionable mutations. These results suggest that ctDNA analysis is a potential alternative and/or replacement to analyses using costly, harmful and lengthy tissue biopsies of metastasis, irrespective of cancer type and metastatic site, for multiplexed mutation detection in selecting personalized therapies based on the patient's tumor genetic content.
Sentiment: Strong Buy
2015 Feb 19. [Epub ahead of print]
Circulating Tumor Cells in Lung Cancer: Detection Methods and Clinical Applications.
Yu N1, Zhou J, Cui F, Tang X.
Circulating tumor cells (CTCs) are tumor cells that have disseminated from primary and metastatic sites, and circulate in the bloodstream. Advanced immunological and molecular-based methods can be used to detect and analyze the cells with the characteristics of tumor cells, and can be detected and analyzed in the blood of cancer patients. The most commonly used methods in lung cancer combine the processes of immunomagnetic enrichment and immunocytochemical detection, morphology-based enrichment coupled with reverse transcriptase polymerase chain reaction (RT-PCR), and RT-PCR alone. CTC analysis is considered a liquid biopsy approach for early diagnosis, risk stratification, evaluation of curative efficacy, and early detection of lung cancer relapse. In this review, we discuss the present techniques for analyzing CTCs, and the restrictions of using these methods in lung cancer. We also review the clinical studies in lung cancer and discuss the underlying associations between these studies and their future applications to this disease.
Sentiment: Strong Buy
In the next year or two, doctors will begin routinely monitoring cancer using a potentially revolutionary technique that searches for a genetic signature in a blood sample, according to experts in the field.
Thanks to lws to have find the article...
The new method, known as a "liquid biopsy," holds the promise of detecting the reappearance of cancer much earlier and more accurately than current methods. And in years to come, this method could also provide a better, less invasive way to diagnose disease than a tissue biopsy.
"This is a very important development that has the potential to transform the way that we see cancer and the way that we treat it," said Steve Shak, chief scientific officer for Genomic Health, a Redwood City. Calif., company that has been testing liquid biopsy techniques and plans to bring one to a clinical trial in 2016. While some of the early liquid biopsy studies have been in breast and prostate cancer, Shak added, "this is a technology we believe will have an impact on all tumor types."
So far the technique has been used on a relatively small number of cancer patients. Biocept, a San Diego firm, performs liquid biopsies on patients with breast, lung and gastric cancers; the company had completed about 400 of the biopsies by the end of 2014. Michael Nall, Biocept's president and chief executive officer, said the technique also offers doctors a better way to detect when a patient's cancer has spread to areas that are more difficult to access for tissue biopsies.
Nall said researchers hope the new biopsy method will translate into longer survival rates for various cancers, though he cautioned, "at this point there's more research that needs to be done to prove that."
Medicine struggles when it comes to monitoring cancers. For prostate cancer, doctors measure what's called the prostate-specific antigen, a protein that's used as a surrogate for the volume of cancer...
Sentiment: Strong Buy
Building on the foundations put in place by doctors like Lo, commercial interest in liquid biopsies has recently started to explode. Eric Topol, a professor of genomics at the Scripps Research Institute, predicted this January that the technology, applied to cancer and other diseases, will become the “stethoscope for the next 200 years.” Jay Flatley, CEO of Illumina, the San Diego company that builds fast gene-sequencing machines, told investors this year that the market for such tests could be worth at least $40 billion. Calling the technology “perhaps the most exciting breakthrough” in cancer diagnostics, he said his company would begin offering researchers a liquid-biopsy test kit to facilitate the search for signs of cancer.
???...The potential value of this company is only this clinical trial...And there 's no post about his title in the entire message board...Which are your information or suggestion about this company?...Thanks???...
ARCA Biopharma, Inc.
Several studies have shown that patients with advanced NSCLC and with activating EGFR mutations have higher response rates to EGFR tyrosine kinase inhibitor (TKI) therapy. Karachaliou et al. demonstrated the relationship between EGFR mutation status as determined by analysis of cfDNA and outcomes. Importantly, the cfDNA data are consistent with mutation data from tissue samples in showing that although both EGFR mutation types benefit from TKI therapy, exon 19 deletions have higher median PFS and OS than L858R mutations.
Other studies similarly show different outcomes depending on the type of EGFR mutation. The IPASS trial examined gefitinib, LUX-3 and LUX-6 studied afatinib, and JO25567 compared erlotinib alone or in combination with bevacizumab; all demonstrated greater benefits of TKI therapy in patients with exon 19 deletions. The mechanism to explain the observed differences remains unclear. Given the negative prognostic indication, patients with L858R mutations should be considered for more aggressive treatment strategies, such as targeting EGFR with afatinib plus cetuximab or higher doses of TKIs.
Detection of EGFR mutation in cfDNA has advantages over tissue biopsy. First, tumor samples are limited and biopsy procedures carry the risk of complications. The cfDNA “liquid biopsy” offers a noninvasive procedure that has potential for use in serial evaluations, rarely feasible with biopsies. Serial evaluations could monitor the emergence of drug resistance, such as the second site mutation at position T790M in EGFR, the most common mechanism of acquired resistance to TKI therapy. Finally, cfDNA provides information on the entire tumor landscape, including primary and metastatic cells, unlike tissue biopsy, which is confined to one tumor site. Given the heterogeneity of most lung cancers, a broad analysis would have benefits in devising optimal treatment strategies. Detecting specific mutations in cfDNA may help to identify patients who will respond better to alternative treatments.
Back in Bioc...end of the correctionis near ...And liquid biopsy is entering the main stage...
More broadly, the potential benefits of liquid biopsies include a better evaluation of the tumor genome landscape with the identification of a comprehensive set of targetable mutations and the serial noninvasive monitoring, which may allow the detection of additional mutations from emerging subclones, including those involved in the development of acquired resistance. Finally, the presence of specific mutations in cfDNA may help identify populations of patients who are likely to have worse (or better) outcomes and who may require alternative treatments.